-
Indian Journal of Pharmacology 2021
Topics: Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; India; Legislation, Medical; Practice Patterns, Physicians'; Ranitidine
PubMed: 33976005
DOI: 10.4103/ijp.ijp_929_20 -
Inflammopharmacology Jun 2016The black cumin or Nigella sativa L. seeds have many acclaimed medicinal properties such as bronchodilatory, hypotensive, antibacterial, antifungal, analgesic,... (Review)
Review
The black cumin or Nigella sativa L. seeds have many acclaimed medicinal properties such as bronchodilatory, hypotensive, antibacterial, antifungal, analgesic, anti-inflammatory and immunopotentiating. This review article is an update on the previous article published on Nigella sativa L. in this journal in 1999. It covers the medicinal properties and chemical syntheses of the alkaloids isolated from the seeds of the herb.
Topics: Analgesics; Animals; Anti-Ulcer Agents; Antineoplastic Agents; Humans; Nigella sativa; Plant Extracts; Seeds
PubMed: 27068721
DOI: 10.1007/s10787-016-0262-7 -
Pharmacotherapy Oct 2003Since their introduction into clinical practice in the 1980s, proton pump inhibitors (PPIs) have proved to be of enormous value in the management of acid peptic... (Review)
Review
Since their introduction into clinical practice in the 1980s, proton pump inhibitors (PPIs) have proved to be of enormous value in the management of acid peptic disorders. They have become the treatment of choice for most, if not all, acid-related gastrointestinal disorders, including gastroesophageal reflux disease, peptic ulcer, and Zollinger-Ellison syndrome. With approval of an intravenous formulation, the benefits of PPIs are extended to critically ill patients for whom oral drug administration is often unsuitable. Five PPIs are approved for clinical use in the United States. Although they share a common core structure and mechanism of action, it is important to understand the general pharmacology of these agents and how they differ from histamine2-receptor antagonists in order to optimize PPI therapy.
Topics: Administration, Oral; Animals; Anti-Ulcer Agents; Clinical Trials as Topic; Drug Interactions; Food-Drug Interactions; Gastric Acid; Humans; Injections, Intravenous; Peptic Ulcer; Proton Pump Inhibitors; Proton Pumps
PubMed: 14587961
DOI: 10.1592/phco.23.13.74s.31929 -
The Yale Journal of Biology and Medicine 1994
Review
Topics: Antacids; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Acid; Humans
PubMed: 7502536
DOI: No ID Found -
Alimentary Pharmacology & Therapeutics Aug 1999Patients with acid-related diseases often need to take multiple medications. Treatment of Helicobacter pylori infection often includes either a histamine type 2... (Review)
Review
Patients with acid-related diseases often need to take multiple medications. Treatment of Helicobacter pylori infection often includes either a histamine type 2 (H2)-receptor antagonist or a proton pump (H+,K(+)-ATPase) inhibitor (proton pump inhibitor), administered in conjunction with one or more antimicrobials. Also, treatment for acid-related diseases often requires extended therapy during which many concomitant medications may be administered for concurrent disease states. Polypharmacy may be the result, particularly in elderly patients, who are at increased risk for both acid-related and many other diseases. Thus, it is important to understand the potential for clinically significant drug-drug interactions in this setting. H2-receptor antagonists and proton pump inhibitors can influence the pharmacokinetic profiles of other commonly administered medications by elevating intragastric pH, which can alter drug absorption, and by interacting with the cytochrome P (CYP) 450 enzyme system, which can affect drug metabolism and clearance. Such interactions are particularly important when they affect the pharmacokinetics of drugs with narrow therapeutic ranges (e.g. warfarin, digoxin). In these cases, drug-drug interactions can result in significant toxicity and even death. There are marked differences among H2-receptor antagonists and proton pump inhibitors in their potential for such interactions. The oldest drugs in each class, cimetidine and omeprazole, respectively, have the greatest potential to alter CYP activity and change the pharmacokinetics of other drugs. The most recently developed H2-receptor antagonist, famotidine, and the newer proton pump inhibitors, rabeprazole and pantoprazole, are much less likely to induce or inhibit CYP and thereby change the metabolism of other medications. These differences are important when choosing medications for the safe treatment of patients with acid-related diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Enzyme Inhibitors; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole
PubMed: 10491725
DOI: 10.1046/j.1365-2036.1999.00021.x -
Alimentary Pharmacology & Therapeutics Jul 2003Rebamipide exerts a positive effect on the digestive epithelial barrier by reinforcing its integrity in normal and in inflammatory conditions, and by normalizing the... (Review)
Review
Rebamipide exerts a positive effect on the digestive epithelial barrier by reinforcing its integrity in normal and in inflammatory conditions, and by normalizing the macromolecular transport across this barrier, increased by Helicobacter infection. Moreover, in mice, rebamipide is capable of diminishing allergic sensitization and of counteracting the inhibitory effect of Helicobacter pylori on oral tolerance to dietary antigens. These properties of rebamipide could explain its anti-inflammatory activity with respect to the digestive mucosa and could provide protection against allergic sensitization to foreign antigens in susceptible individuals.
Topics: Alanine; Anti-Ulcer Agents; Antigens, Bacterial; Biological Transport; Digestive System; Epithelial Cells; Helicobacter pylori; Humans; Intestinal Absorption; Quinolones
PubMed: 12925141
DOI: 10.1046/j.1365-2036.18.s1.6.x -
Digestive Diseases and Sciences May 2006
Review
Topics: Anti-Ulcer Agents; Enzyme Inhibitors; Gastric Acid; H(+)-K(+)-Exchanging ATPase; Helicobacter pylori; Humans; Imidazoles; Molecular Structure; Peptic Ulcer; Proton Pump Inhibitors
PubMed: 16645899
DOI: 10.1007/s10620-005-9042-8 -
Japanese Journal of Pharmacology Apr 1991Effects of a new antiulcer drug, MCI-727, on gastric and duodenal lesions, gastric secretion and gastric motility were studied in comparison with cimetidine and...
Effects of a new antiulcer drug, MCI-727, on gastric and duodenal lesions, gastric secretion and gastric motility were studied in comparison with cimetidine and teprenone. MCI-727 dose-dependently (3-100 mg/kg, p.o. or i.d.) inhibited the development of acute gastric or duodenal lesions such as pyrolus ligation-, water-immersion stress-, indomethacin-, HCl-, HCl-ethanol-induced gastric lesions and cysteamine-induced duodenal lesions in rats and histamine-induced duodenal lesions in guinea pigs. These antiulcer effects exceeded those of cimetidine or teprenone. Repeated administration of MCI-727 (0.3-3 mg/kg/day, p.o., for 10 days) significantly promoted the spontaneous healing of acetic acid-induced chronic gastric ulcers. Concerning gastric acid secretion, MCI-727 selectively inhibited tetragastrin-stimulated acid secretion without effecting basal acid secretion and acid secretion by other stimuli. Cimetidine and teprenone inhibited acid secretion in several cases. MCI-727 and teprenone had inhibitory effects on gastric motility, although cimetidine had no effect. These results suggest that MCI-727 has a wide spectrum of antiulcer activity, and its mode of antiulcer action is different from that of cimetidine or teprenone.
Topics: Animals; Anti-Ulcer Agents; Cimetidine; Diterpenes; Duodenal Ulcer; Female; Gastric Mucosa; Gastrointestinal Motility; Guinea Pigs; Immersion; Male; Oximes; Piperazines; Rats; Rats, Inbred Strains; Stomach Ulcer; Stress, Psychological
PubMed: 1886287
DOI: 10.1254/jjp.55.415 -
Chemical & Pharmaceutical Bulletin 2011A new series of novel (2S)-2-({2-[1,4-dihydro-3,5-bis(methoxycarbonyl)-2,6-dimethyl-4-(2-nitrophenyl)pyridin-1-yl]-2-oxoethyl}amino)-3-(4-hydroxyphenyl) propanoic acid...
A new series of novel (2S)-2-({2-[1,4-dihydro-3,5-bis(methoxycarbonyl)-2,6-dimethyl-4-(2-nitrophenyl)pyridin-1-yl]-2-oxoethyl}amino)-3-(4-hydroxyphenyl) propanoic acid (3a) and its analogues 3b-j has been synthesized. These compounds were evaluated for their in vitro antioxidant activity, anti-inflammatory activity and antiulcer activity. Compounds 3b and f exhibited significant antioxidant action comparable with that of standard. Efficacy against inflammation and ulceration was also found to be significant. The chemical structures of these compounds were confirmed on the basis of spectral data.
Topics: Amino Acids; Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antioxidants; Butyrates; Nifedipine; Pyridines; Structure-Activity Relationship
PubMed: 21881260
DOI: 10.1248/cpb.59.1153 -
A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease.The American Journal of Managed Care May 2000Proton pump inhibitors (PPIs) are the drugs of choice for treating gastroesophageal reflux disease (GERD). Their superiority to histamine2 receptor antagonists (H2RAs),... (Review)
Review
Proton pump inhibitors (PPIs) are the drugs of choice for treating gastroesophageal reflux disease (GERD). Their superiority to histamine2 receptor antagonists (H2RAs), cisapride, and sucralfate is directly related to their potent and prolonged suppression of gastric acid. The PPIs provide the most rapid relief of GERD symptoms and esophageal healing when compared with standard- or high-dose H2RAs or cisapride. Their superiority over H2RAs has also been demonstrated when used in maintaining esophageal healing and symptom relief. The cost effectiveness of standard-dose PPIs in the treatment of GERD has been well documented. High-dose PPI therapy may benefit patients with atypical GERD symptoms and may also be cost effective. Four PPIs are available in the United States: omeprazole, lansoprazole, rabeprazole, and pantoprazole. All 4 PPIs, when used in recommended dosages, are very effective for the acute and chronic treatment of GERD and demonstrate similar short- and long-term safety profiles. Subtle differences appear to exist, some of which are based on data obtained in vitro or from healthy volunteer studies and others on trends or relatively minor differences observed in selective clinical trials. In most cases, experience has not yet confirmed the clinical importance of these potential differences. The selection of a preferred PPI for a hospital or managed care formulary will most likely be based on the acquisition cost of the drug.
Topics: Anti-Ulcer Agents; Drug Therapy, Combination; Evaluation Studies as Topic; Gastroesophageal Reflux; Humans; Proton Pump Inhibitors
PubMed: 10977489
DOI: No ID Found